## Il Han Choo

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/740617/publications.pdf

Version: 2024-02-01

279798 276875 83 1,848 23 41 citations h-index g-index papers 127 127 127 3336 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The Korean Medication Algorithm Project for Depressive Disorder 2021: Comparisons with Other Treatment Guidelines. Clinical Psychopharmacology and Neuroscience, 2022, 20, 37-50.	2.0	7
2	A Single Baseline Amyloid Positron Emission Tomography Could Be Sufficient for Predicting Alzheimer's Disease Conversion in Mild Cognitive Impairment. Psychiatry Investigation, 2022, 19, 394-400.	1.6	1
3	Korean Medication Algorithm Project for Bipolar Disorder 2022: Depressive Episode. Journal of Korean Neuropsychiatric Association, 2022, 61, 123.	0.5	O
4	Korean Medication Algorithm Project for Bipolar Disorder 2022: Overview. Journal of Korean Neuropsychiatric Association, 2022, 61, 98.	0.5	1
5	Korean Medication Algorithm Project for Bipolar Disorder 2022: Manic Episode. Journal of Korean Neuropsychiatric Association, 2022, 61, 110.	0.5	O
6	Korean Medication Algorithm Project for Bipolar Disorder 2022: Mixed Features. Journal of Korean Neuropsychiatric Association, 2022, 61, 133.	0.5	0
7	Korean Medication Algorithm Project for Depressive Disorder 2021 (II): The Subtypes of Depression. Journal of Korean Neuropsychiatric Association, 2021, 60, 186.	0.5	O
8	Korean Medication Algorithm Project for Depressive Disorder 2021 (III): Child and Adolescent. Journal of Korean Neuropsychiatric Association, 2021, 60, 193.	0.5	0
9	Korean Medication Algorithm Project for Depressive Disorder 2021 (I): Treatment Strategies for Major Depressive Episode. Journal of Korean Neuropsychiatric Association, 2021, 60, 174.	0.5	1
10	Korean Medication Algorithm for Depressive Disorder 2021, Fourth Revision: An Executive Summary. Clinical Psychopharmacology and Neuroscience, 2021, 19, 751-772.	2.0	7
11	Korean Medication Algorithm Project for Depressive Disorder 2021 (V): Antidepressant Choices According to Safety, Adverse Effect, Comorbid Physical Illnesses and Clinical Definition of Treatment Resistant Depression. Journal of Korean Neuropsychiatric Association, 2021, 60, 267.	0.5	O
12	Korean Medication Algorithm Project for Depressive Disorder 2021 (IV): Female and Elderly. Journal of Korean Neuropsychiatric Association, 2021, 60, 258.	0.5	O
13	Korean Medication Algorithm Project for Depressive Disorder 2021 (VI): Non-Pharmacological Biological Treatments. Journal of Korean Neuropsychiatric Association, 2021, 60, 275.	0.5	O
14	Quantitative analysis of amyloid PET or FDGâ€PET showed differences in aMCI to AD convert group. Alzheimer's and Dementia, 2021, 17, .	0.8	1
15	Only baseline amyloid burdens and their incremental change could not predict AD progression in mild cognitive impairment. Alzheimer's and Dementia, 2021, $17$ , .	0.8	O
16	The normative data of cortical volumes in normal aging from Neuro I, a brain image quantitative analysis system. Alzheimer's and Dementia, $2021,17,.$	0.8	0
17	Visual field defects as early symptoms of Alzheimer's disease Alzheimer's and Dementia, 2021, 17 Suppl 3, e053704.	0.8	O
18	The Aging Slopes of Brain Structures Vary by Ethnicity and Sex: Evidence From a Large Magnetic Resonance Imaging Dataset From a Single Scanner of Cognitively Healthy Elderly People in Korea. Frontiers in Aging Neuroscience, 2020, 12, 233.	3.4	17

#	Article	IF	CITATIONS
19	Correlation between depressive symptom and executive function decline in amyloid positive mild cognitive impairment. Alzheimer's and Dementia, 2020, 16, e037745.	0.8	0
20	Experiences of caregivers of people with dementia participating in a communityâ€based dementia caregiver program. Alzheimer's and Dementia, 2020, 16, e039002.	0.8	0
21	Neural Correlates of Self-referential Processing and Their Clinical Implications in Social Anxiety Disorder. Clinical Psychopharmacology and Neuroscience, 2019, 17, 12-24.	2.0	24
22	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. Journal of Neurology, 2019, 266, 2535-2545.	3.6	11
23	Distinct Neural Correlates of Executive Function by Amyloid Positivity and Associations with Clinical Progression in Mild Cognitive Impairment. Yonsei Medical Journal, 2019, 60, 935.	2.2	4
24	Association of Subjective Memory Complaints with the Left Parahippocampal Amyloid Burden in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2019, 72, 1261-1268.	2.6	2
25	P1â€434: APOE PROMOTER POLYMORPHISM ACTS AS AN EFFECT MODIFIER FOR APOE Îμ4 ON ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P476.	0.8	0
26	Pre-Mild Cognitive Impairment: Can Visual Memory Predict Who Rapidly Convert to Mild Cognitive Impairment?. Psychiatry Investigation, 2018, 15, 869-875.	1.6	15
27	Association of subjective memory complaint and depressive symptoms with objective cognitive functions in prodromal Alzheimer's disease including pre-mild cognitive impairment. Journal of Affective Disorders, 2017, 217, 24-28.	4.1	23
28	[P2â€"348]: THE ASIAN ELDERLY ARE MORE SUSCEPTIBLE TO APOE ε4â€ĐEPENDENT ONSET OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P755.	0.8	1
29	[P3–285]: PREâ€MILD COGNITIVE IMPAIRMENT: CAN MEMORY PREDICT WHO RAPIDLY CONVERTS TO MILD COGNITIVE IMPAIRMENT?. Alzheimer's and Dementia, 2017, 13, P1052.	0.8	0
30	[P1–278]: AGEâ€WEIGHTED POLYGENIC RISK MODEL EFFECTIVELY PREDICTS THE ONSET OF ALZHEIMER DISEALZHEIMER DISEALZH	ASE 0.8	0
31	Structural MRI and Amyloid PET Imaging for Prediction of Conversion to Alzheimer's Disease in Patients with Mild Cognitive Impairment: A Meta-Analysis. Psychiatry Investigation, 2017, 14, 205.	1.6	15
32	Independent and Interactive Influences of the <i>APOE</i> Genotype and Beta-Amyloid Burden on Cognitive Function in Mild Cognitive Impairment. Journal of Korean Medical Science, 2016, 31, 286.	2.5	11
33	Topographical APOE É>4 Genotype Influence on Cerebral Metabolism in the Continuum of Alzheimer's Disease: Amyloid Burden Adjusted Analysis. Journal of Alzheimer's Disease, 2016, 54, 559-568.	2.6	7
34	Altered Executive Function in Pre-Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2016, 54, 933-940.	2.6	38
35	P2â€234: APOE E4 Genotype Influence on Cerebral Metabolism in Mild Cognitive Impairment: Amyloid Burden–Adjusted Analysis. Alzheimer's and Dementia, 2016, 12, P713.	0.8	0
36	ICâ€Pâ€067: APOEâ€E4 Genotype Influence on Cerebral Metabolism in Mild Cognitive Impairment: Amyloid Burden Adjusted Analysis. Alzheimer's and Dementia, 2016, 12, P53.	0.8	0

#	Article	IF	Citations
37	P3â€217: Subjective Depressive Symptoms are Associated with Objective Memory Decline in Preclinical Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P908.	0.8	О
38	Amyloid-independent functional neural correlates of episodic memory in amnestic mild cognitive impairment. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1088-1095.	6.4	10
39	P1-149: Structural MRI and amyloid PET imaging for prediction of conversion to Alzheimer's disease in patients with mild cognitive impairment: A meta-analysis. , 2015, 11, P400-P400.		O
40	P1-142: Independent and interactive influences of ApoE genotype and beta-amyloid burden on cognitive functions in mild cognitive impairment., 2015, 11, P396-P397.		0
41	P3-120: Separate functional neural correlates of memory deficits in amnestic mild cognitive impairment with high and low beta-amyloid burden. , 2015, 11, P668-P668.		0
42	IC-P-070: Separate functional neural correlates of memory deficits in amnestic mild cognitive impairment with high and low beta-amyloid burden., 2015, 11, P52-P53.		0
43	Prediction of AD dementia by biomarkers following the NIAâ€AA andÂIWG diagnostic criteria in MCI patients from three European memory clinics. Alzheimer's and Dementia, 2015, 11, 1191-1201.	0.8	71
44	IC-P-104: Structural MRI and amyloid PET imaging for prediction of conversion to Alzheimer's disease in patients with mild cognitive impairment: A meta-analysis., 2015, 11, P71-P72.		0
45	P2-205: Neuropsychological characteristics of clinical dementia rating 0.5 with uncertain impairment. , 2015, 11, P571-P571.		0
46	Factors Associated with Health-Related Quality of Life Among Overweight and Obese Korean Women. Women and Health, 2015, 55, 152-166.	1.0	9
47	Psychiatric Symptoms in Temporal Lobe Epilepsy with Left Mesial Hippocampal Sclerosis. Psychiatry Investigation, 2015, 12, 274.	1.6	3
48	Electroconvulsive Therapy in a Case of Gender Dysphoria Patient with Severe Mood Dysregulation and Suicidal Ideation. Journal of Korean Neuropsychiatric Association, 2014, 53, 54.	0.5	2
49	Astrocytosis measured by 11C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2120-2126.	6.4	53
50	Healthâ€promoting behaviour among women with abdominal obesity: a conceptual link to social support and perceived stress. Journal of Advanced Nursing, 2014, 70, 1381-1390.	3.3	33
51	Novel N-biphenyl-2-ylmethyl 2-methoxyphenylpiperazinylalkanamides as 5-HT7R antagonists for the treatment of depression. Bioorganic and Medicinal Chemistry, 2014, 22, 4587-4596.	3.0	21
52	Novel thienopyrimidinones as mGluR1 antagonists. European Journal of Medicinal Chemistry, 2014, 85, 629-637.	5.5	11
53	Improvement of Screening Accuracy of Mini-Mental State Examination for Mild Cognitive Impairment and Non-Alzheimer's Disease Dementia by Supplementation of Verbal Fluency Performance. Psychiatry Investigation, 2014, 11, 44.	1.6	17
54	Electroconvulsive Therapy in a Case of Gender Dysphoria Patient with Severe Mood Dysregulation and Suicidal Ideation. Journal of Korean Neuropsychiatric Association, 2014, 53, 54.	0.5	0

#	Article	IF	CITATIONS
55	Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson's disease. Bioorganic and Medicinal Chemistry, 2013, 21, 5480-5487.	3.0	33
56	Aryl Biphenylâ€3â€ylmethylpiperazines as 5â€HT <sub>7</sub> Receptor Antagonists. ChemMedChem, 2013, 8, 1855-1864.	3.2	12
57	Combination of 18F-FDG PET and Cerebrospinal Fluid Biomarkers as a Better Predictor of the Progression to Alzheimer's Disease in Mild Cognitive Impairment Patients. Journal of Alzheimer's Disease, 2013, 33, 929-939.	2.6	48
58	Improvement of Dementia Screening Accuracy of Mini-Mental State Examination by Education-Adjustment and Supplementation of Frontal Assessment Battery Performance. Journal of Korean Medical Science, 2013, 28, 1522.	2.5	13
59	Violence Frequency by Sexual Assault Characteristics. Journal of Korean Neuropsychiatric Association, 2013, 52, 360.	0.5	0
60	Normative study of the category fluency test (CFT) from nationwide data on community-dwelling elderly in Korea. Archives of Gerontology and Geriatrics, 2012, 54, 305-309.	3.0	10
61	Microstructural Alteration of the Anterior Cingulum is Associated With Apathy in Alzheimer Disease. American Journal of Geriatric Psychiatry, 2011, 19, 644-653.	1.2	65
62	Relationship of Amyloid-Beta Burden With Age-At-Onset in Alzheimer Disease. American Journal of Geriatric Psychiatry, 2011, 19, 627-634.	1.2	32
63	Prevalence of neuropsychiatric syndromes in Alzheimer's disease (AD). Archives of Gerontology and Geriatrics, 2011, 52, 258-263.	3.0	33
64	Neural Correlates of Stroop Performance in Alzheimer's Disease: A FDG-PET Study. Dementia and Geriatric Cognitive Disorders Extra, 2011, 1, 190-201.	1.3	19
65	Discrimination of normal aging, MCI and AD with multimodal imaging measures on the medial temporal lobe. Psychiatry Research - Neuroimaging, 2010, 183, 237-243.	1.8	37
66	Total Scores of the CERAD Neuropsychological Assessment Battery: Validation for Mild Cognitive Impairment and Dementia Patients With Diverse Etiologies. American Journal of Geriatric Psychiatry, 2010, 18, 801-809.	1.2	84
67	Posterior cingulate cortex atrophy and regional cingulum disruption in mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2010, 31, 772-779.	3.1	178
68	Korean Version of Mini Mental Status Examination for Dementia Screening and Its' Short Form. Psychiatry Investigation, 2010, 7, 102.	1.6	221
69	Frontal Dysfunction Underlies Depression in Mild Cognitive Impairment: A FDG-PET Study. Psychiatry Investigation, 2010, 7, 208.	1.6	26
70	Prevalence of Mild Cognitive Impairment and Its Subtypes Are Influenced by the Application of Diagnostic Criteria: Results from the Korean Longitudinal Study on Health and Aging (KLoSHA). Dementia and Geriatric Cognitive Disorders, 2009, 28, 23-29.	1.5	32
71	Development of the Subjective Memory Complaints Questionnaire. Dementia and Geriatric Cognitive Disorders, 2009, 27, 310-317.	1.5	144
72	The prevalence of cognitive impairment with no dementia in older people: The seoul study. International Journal of Geriatric Psychiatry, 2009, 24, 306-312.	2.7	10

#	Article	IF	CITATION
73	Prevalence and neuropsychiatric comorbidities of alcohol use disorders in an elderly Korean population. International Journal of Geriatric Psychiatry, 2009, 24, 1420-1428.	2.7	23
74	Neural Correlates of the Clock Drawing Test Performance in Alzheimer's Disease: A FDG-PET Study. Dementia and Geriatric Cognitive Disorders, 2008, 26, 306-313.	1.5	37
75	Prevalence of Dementia and Its Subtypes in an Elderly Urban Korean Population: Results from the Korean Longitudinal Study on Health and Aging (KLoSHA). Dementia and Geriatric Cognitive Disorders, 2008, 26, 270-276.	1.5	79
76	Lack of Association Between Apolipoprotein E Polymorphism and Vascular Dementia in Koreans. Journal of Geriatric Psychiatry and Neurology, 2008, 21, 12-17.	2.3	23
77	Topographic Patterns of Brain Functional Impairment Progression According to Clinical Severity Staging in 116 Alzheimer Disease Patients: FDG-PET Study. Alzheimer Disease and Associated Disorders, 2007, 21, 77-84.	1.3	52
78	Frontal Dysfunction Underlies Depressive Syndrome in Alzheimer Disease: A FDG-PET Study. American Journal of Geriatric Psychiatry, 2006, 14, 625-628.	1.2	46
79	Combination of Clinical and Neuropsychologic Information as a Better Predictor of the Progression to Alzheimer Disease in Questionable Dementia Individuals. American Journal of Geriatric Psychiatry, 2006, 14, 130-138.	1.2	22
80	White Matter Changes Associated With Psychotic Symptoms in Alzheimer's Disease Patients. Journal of Neuropsychiatry and Clinical Neurosciences, 2006, 18, 191-198.	1.8	39
81	A normative study of the Trail Making Test in Korean elders. International Journal of Geriatric Psychiatry, 2006, 21, 844-852.	2.7	82
82	Lack of association of cathepsin D genetic polymorphism with Alzheimer's disease in Koreans. Archives of Gerontology and Geriatrics, 2005, 41, 121-127.	3.0	6
83	Evaluating the Effectiveness of Community-Based Dementia Caregiver Intervention on Caregiving Burden, Depression, and Attitude Toward Dementia: A Quasiâ€experimental Study. Clinical Interventions in Aging 0. Volume 17, 937-946	2.9	3